Page 6,190«..1020..6,1896,1906,1916,192..6,2006,210..»

Chelsea Therapeutics Announces Results From Northera(TM) (droxidopa) Study in Spinal Cord Injury at the 23rd …

Posted: Published on November 7th, 2012

CHARLOTTE, N.C., Nov. 6, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (CHTP) today announced results from a study of Northera(TM) (droxidopa) in hypotensive individuals with spinal cord injury at the 23rd International Symposium on the Autonomic Nervous System, which took place October 31 through November 3, 2012 in Paradise Island, Bahamas. The poster, titled "Blood Pressure Effect of Droxidopa in Hypotensive Individuals with Spinal Cord Injury," (poster #62) highlighted results of a clinical study designed to determine the blood pressure effect of escalating doses of droxidopa (100 mg, 200 mg & 400 mg) during three laboratory visits in hypotensive subjects (n=10) with spinal cord injury (SCI). The level of SCI ranged from cervical to low thoracic lesions, all were chronically injured and non-ambulatory and 8 were motor complete. Subjects were hypotensive at baseline (systolic BP: 87+/-14 mmHg; diastolic BP: 54+/-8 mmHg), and baseline BP did not differ among the 3 visits. Upon supine repositioning prior to drug administration, BP increased significantly (SBP: 101+/-11 mmHg; DBP: 62+/-7 mmHg; p … Continue reading

Posted in Spinal Cord Injury Treatment | Comments Off on Chelsea Therapeutics Announces Results From Northera(TM) (droxidopa) Study in Spinal Cord Injury at the 23rd …

Research and Markets: Global Parkinson's Disease Epidemiology and Patient Flow Analysis – 2012

Posted: Published on November 7th, 2012

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/88l8xd/global) has announced the addition of the "Global Parkinson's Disease Epidemiology and Patient Flow Analysis - 2012" report to their offering. Fore Pharma announced the results of its Parkinson's Disease patient population study in a new report Global Parkinson's Disease Epidemiology and Patient Flow Analysis - 2012'. The report provides insights into Parkinson's Disease epidemiology, Parkinson's Disease diagnosed patients, and Parkinson's Disease treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Parkinson's Disease derived from epidemiological analysis, percentage of patients diagnosed with Parkinson's Disease, and percentage of patients treated with Parkinson's Disease therapy. The study helps executives estimate Parkinson's Disease market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions. The report provides estimates and forecasts of Parkinson's Disease prevalence, Parkinson's Disease diagnosis rate, and Parkinson's Disease treatment rate for the period 2012-2019. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and Japan. The study design is based on collection and interpretation of data from … Continue reading

Posted in Parkinson's Treatment | Comments Off on Research and Markets: Global Parkinson's Disease Epidemiology and Patient Flow Analysis – 2012

Cerebral palsy – causes, types, diagnosis, therapy – Video

Posted: Published on November 7th, 2012

Cerebral palsy - causes, types, diagnosis, therapy Cerebral palsy - causes, types, diagnosis, therapy by health.india.com. Developmental pediatrician Dr Leena Deshpande tells us about cerebral palsy and how the parents of a child with this condition could deal with it. She can be consulted online at http://www.mediangels.comFrom:healthindiavideosViews:0 0ratingsTime:05:46More inHowto Style Here is the original post: Cerebral palsy - causes, types, diagnosis, therapy - Video … Continue reading

Posted in Cerebral Palsy Treatment | Comments Off on Cerebral palsy – causes, types, diagnosis, therapy – Video

New York Brain Injury Attorney Says Brain Injuries are a Public Health Crisis

Posted: Published on November 7th, 2012

Brain injury attorney Michael V. Kaplen analyses recent statistics on the extent and cost of brain injury. Pleasantville, NY (PRWEB) November 07, 2012 Citing the report titled Traumatic Brain Injury: Occurrence and Mortality in New Hampshire based on 2001-2009 surveillance data issued by the Department of Health and Human Services which found that the number of people taken to emergency rooms for brain trauma almost doubled, from 6,514 to 12,306 from 2001 to 2009 and half of those patients were younger than 24, with most injuries occurring as a result of car accidents, sports, and other high-risk activities prevalent among the young, Kaplen said that the epidemic of traumatic brain injury requires immediate government attention with a renewed priority. According to the report, senior citizens are also at high risk for brain injury. Brain trauma for elder citizens is most frequently caused by falls and the number of emergency-room patients increased by approximately 150 percent for persons over 45 years of age. While there was a dramatic increase in emergency room visits, as well as a similar increase in hospital in-patient stays, the report indicates that the number of deaths from traumatic brain injury rose only slightly only in the … Continue reading

Posted in Brain Injury Treatment | Comments Off on New York Brain Injury Attorney Says Brain Injuries are a Public Health Crisis

New MS drug proves effective where others have failed

Posted: Published on November 7th, 2012

Public release date: 31-Oct-2012 [ | E-mail | Share ] Contact: Genevieve Maul Genevieve.maul@admin.cam.ac.uk 44-012-237-65542 University of Cambridge A drug which 'reboots' a person's immune system has been shown to be an effective treatment for multiple sclerosis (MS) patients who have already failed to respond to the first drug with which they were treated (a 'first-line' therapy), as well as affected individuals who were previously untreated. The results of these two phase III clinical trials were published today in the journal The Lancet. The new studies, sponsored by Genzyme (a Sanofi company) and Bayer Schering Pharma, showed that alemtuzumab significantly reduces the number of attacks (or relapses) experienced by people with MS compared to interferon beta-1a (known commercially as Rebif). This was seen both in patients who had not previously received any treatment (drug-nave) and those who have continued to show disease activity whilst taking an existing treatment for MS. In the CARE MSII trial, confined to patients who had recently relapsed on a licenced therapy, new episodes were reduced by 49 per cent more than that achieved by the current standard treatment for MS, interferon beta-1a. Over a two year period, 65 per cent of patients on alemtuzumab compared … Continue reading

Posted in MS Treatment | Comments Off on New MS drug proves effective where others have failed

New Data On The Challenges Of Cost Effectiveness Modeling In Paediatric Use Marketing Authorisation (PUMA) HTA …

Posted: Published on November 7th, 2012

- Health Technology Assessment (HTA) Bodies may need to review their requirements when assessing products that have been granted a PUMA - - Buccolam (Midazolam, Oromucosal Solution) was the first medicine to be granted a PUMA and has received positive recommendations by two HTA bodies in Europe - BRUSSELS, Nov. 5, 2012 /PRNewswire/ -- ViroPharma Incorporated today announced the presentation of a poster on cost effectiveness considerations in submissions for therapeutics targeting small patient populations, including those considered under the new Paediatric Use Marketing Authorisation (PUMA) process. These data were presented at the 15th Annual Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), held November 3 - 7 in Berlin, Germany. The PUMA approval process differs from a traditional marketing authorisation, as it will often be based upon population subsets, as is often seen in orphan drug product development. In the case of Buccolam (Midazolam, Oromucosal Solution), in order to help inform the HTA, primary data gathering was required to gain information on cost effectiveness, the results and approach of which have been accepted by two HTA bodies (the Scottish Medicines Consortium and All Wales Medicines Strategy Group). These data included expert views on the treatment pathways … Continue reading

Comments Off on New Data On The Challenges Of Cost Effectiveness Modeling In Paediatric Use Marketing Authorisation (PUMA) HTA …

About Hormones

Posted: Published on November 7th, 2012

About Hormones Update! 3:53 - Frequent question answered. (Can i take what your taking to grow boobs?) Excuse the no makeup. It's nice to be natural sometimes! Basically a video of my explaining how HRT (Hormone replacement therapy) works! And of course, my updates!From:princessjoulesViews:9928 297ratingsTime:06:06More inPeople Blogs Read the original post: About Hormones … Continue reading

Posted in Hormone Replacement Therapy | Comments Off on About Hormones

How do I know if I need BHRT? – Video

Posted: Published on November 7th, 2012

How do I know if I need BHRT? Any adult experiencing fatigue, difficulty sleeping, decrease in libido, decreased mental clarity and weight gain, especially around the abdominal area, is an ideal candidate for hormone replacement therapy. Conventional medicine has led us to believe that aging is a natural process that cannot be altered. This is simply not true. Extensive research studies reveal that much can be done to slow the progression and sometimes prevent the diseases associated with aging through the safe, effective use of bio-identical hormone therapy in conjunction with proper nutrition and an active lifestyle.From:t1instituteViews:0 0ratingsTime:00:45More inPeople Blogs View original post here: How do I know if I need BHRT? - Video … Continue reading

Posted in Hormone Replacement Therapy | Comments Off on How do I know if I need BHRT? – Video

stem cell | Banking Cord Blood – Private Or Public? – Video

Posted: Published on November 7th, 2012

stem cell | Banking Cord Blood - Private Or Public? http://www.cordbloodrecommendation.com The blood is taken from your umbilical cord after your baby is delivered and is disconnected from the umbilical cord. For others, having cord blood from a family member can mean a reduction in complications, improved survival, and a better quality of life without the need for continual anti-rejection medications. Pointing out only the pros of banking the cord blood, like stating that this will be a one time shot insurance coverage that you do not want to miss out on. It has been proven to be a better alternative than regular bone marrow transplants. There is much controversy regarding the use of stem cell research as it pertains to the use of embryos. - They are not tumorogenic- Collecting umbilical cord blood does not hurt the patron in any wayFlex Blood saving is not emergent Stem group inquiriesUnfortunately, controversy surrounding budding stem group inquiries undermines the view of cord blood mass room and adult stem group inquiries. This blood is extracted through the use of syringes or can simply be drained from the cord. They (or your partner) can complete the paper work easily, allowing for this life … Continue reading

Posted in Stem Cell Research | Comments Off on stem cell | Banking Cord Blood – Private Or Public? – Video

cord blood banking cost | Cord Blood Storage and Why – Video

Posted: Published on November 7th, 2012

cord blood banking cost | Cord Blood Storage and Why http://www.cordbloodrecommendation.com GENERAL ACCREDITATION IS NOT ENOUGH. A lot of confusing information is purposefully disseminated by companies that overcharge. I'm sure you have a list of all that needs to be done. However, the scenario has changed with the discovery of cord blood stem cells. The bank will sent the pregnant mother a collection kit to bring to the hospital during the delivery. There is higher success rate for transplants done with private umbilical blood donated by close relative compared to public banks. In which way are the stem cells able to overcome this type of disorder? There are a lot of studies which concern on the benefits which this cell can serve for the need of people. Twenty-five children diagnosed with Krabbe's disease were followed and studied regarding their treatments. What's all the fuss about and what does a newborn's umbilical cord have to do with it?The blood within a newborns umbilical cord, called cord blood, plays a critical role in stem cell research. These stem cells operate as main cells as they donate to the growth of all tissues, organs, and systems in the human … Continue reading

Posted in Stem Cell Research | Comments Off on cord blood banking cost | Cord Blood Storage and Why – Video

Page 6,190«..1020..6,1896,1906,1916,192..6,2006,210..»